HEXO Corp Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
Record Revenue in Q420 and FY2020
Achieves Fourth Sequential Quarterly Adjusted EBITDA Improvement
OTTAWA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NYSE: HEXO) (“HEXO” or the "Company") today reported its financial results for the fourth quarter and fiscal year ended July 31, 2020. All amounts are expressed in Canadian dollars unless otherwise noted.
“HEXO’s topline growth this quarter reflects the ongoing performance and success of our 2.0 products and the high quality of our offering which repeatedly resonates with consumers. We are commanding significant market share in Quebec and this year we made major strides by launching Truss cannabis infused beverages in Canada in addition to our initial foray into the U.S. with Molson Coors, a world-class partner,” said Sebastien St-Louis, CEO and co-founder of HEXO.
St-Louis continued, “Our business is improving quarter over quarter as we continue to focus on achieving positive Adjusted EBITDA. In the fourth quarter we also strengthened our balance sheet as we look beyond positive Adjusted EBITDA to positive EPS.”
Key Financial & Operating Highlights from Q420
- Revenue per gram equivalent for non-beverage adult-use sales increased to $4.07 or 29% from the previous quarter,
- Continued market expansion and first quarter of contribution from cannabis beverage products “powered by HEXO” in the fourth quarter, contributing $2.0M of net revenue
- Net revenue of $27.1M, up 23% from the previous quarter and 76% from the same quarter in the prior year
- Gross revenue of $36.1M, the highest in the company’s history, increasing 17% from the previous quarter and 76% from the same quarter in the prior year
- Adjusted EBITDA of ($3.25M), representing a 21% improvement from the previous quarter; tracking towards positive Adjusted EBITDA in the first half of fiscal 2021
- The Company maintained Gross Margin before adjustments of 42%, on sales excluding adult-use beverages, as the Company continued its strategy of providing consumers with high quality, lower priced alternatives
- Increased cash and cash equivalents by 95% from the prior quarter. This was accomplished primarily through the Company’s financing activity in the period where net funds of $54M and $33M were raised through the May 2020 public offering and the June 2020 at-the-market offering, respectively
- The Company’s working capital was $223M, including $184M of cash
- Operational cash use of ($3.8M)1 for the quarter, not including financing and investing activities
- The Company recorded write downs to inventory of $43M to align the Company with future demand and near-term production plan. The Company recorded impairments to property, plant and equipment of $46.4M, right sizing the balance sheet to align with future performance and support a pathway to positive earnings per share
1 Operational cash use was calculated as the change between the cash used in operating actives for the year ended July 31, 2020 as compared the cash used in operating activities for the 9 months ended April 30, 2020.
|For the three months ended||For the twelve months ended|
|Income Statement Snapshot||July 31, 2020||April 30, 2020||July 31, 2019||July 31, 2020||July 31, 2019|
|Revenue from sale of goods||36,140||30,895||20,517||110,149||59,256|
|Net revenue from sale of goods||27,058||22,078||15,395||80,551||47,342|
|Gross (loss)/profit before adjustments1||8,104||8,783||5,133||26,953||21,344|
|Gross (loss)/profit before fair value1 adjustments2||(36,012||)||7,452||(14,202||)||(46,421||)||2,009|
|Loss from operations||(106,199||)||(20,755||)||(63,067||)||(476,551||)||(86,974||)|
|Other income/(expenses and losses)||(63,333||)||1,699||125||(75,961||)||(847||)|
|Net loss before tax||(169,532||)||(19,056||)||(62,942||)||(552,512||)||(87,821||)|
|Total Net loss||(169,532||)||(19,056||)||(44,729||)||(446,489||)||(69,608||)|
|1 Refer to the Company’s “Non-IFRS Measures” section as disclosed in the fiscal 2020 Management’s Discussion and Analysis.|
Fourth Quarter 2020 Highlights
Gross revenue in Q4’20 increased 17% to $36.1M from $30.9M in Q3’20, and 76% from $20.5M in Q4’19. The primary drivers of the increase were the Company’s cannabis 2.0 products, launching cannabis vapes into the market, which is a new sales stream and contributed $1.3M to gross sales, as well as $2.4M of beverage based adult-use sales, another new revenue stream that began mid-fiscal year, and from international sales of $1.3M reflecting the Company’s purchase agreement established with an Israel based medical cannabis company.
Gross margin before fair value adjustments in Q4’20 was 30%, compared with 40% in the prior sequential quarter. While the Company’s gross margin has been trending upward in the year driven by production efficiencies, automation of packaging activities, and choice of strain cultivation, the Company’s adult use beverage launch caused an impact to margins in 4Q20 as operating and overhead costs were recognized in cost of sales without the benefit of fully scaled production and sales. As previously noted, the Company had expected to see fluctuations in gross margins related to new product introductions.
|For the three months ended July 31, 2020||$||$||$||$||$||$||$|
|Cost of sales||13,663||119||642||222||14,646||4,395||19,558|
|Gross profit before adjustments ($)||8,912||429||649||433||10,423||(2,406||)||7,500|
|Gross margin before adjustments (%)||39%||78%||50%||66%||42%||(121%||)||28%|
|For the three months ended April 30, 2020||$||$||$||$||$||$||$|
|Cost of sales||11,826||163||–||198||12,187||1,162||13,349|
|Gross profit before adjustments ($)||8,788||530||–||142||9,460||(731||)||8,729|
|Gross margin before adjustments (%)||43%||76%||–||42%||44%||(170%||)||40%|
Operating expenses were $71.5M in the quarter, and loss from operations for Q420 was $106.2M. Included in Q420 operating expenses were the following items:
- Impairments of property, plant and equipment of $46.4M
- Loss on onerous contract of $1.8M
- Restructuring costs of ($0.1M)
|Total net loss||(169,532||)||(18,837||)||(297,867||)||(60,016||)||(44,729||)|
|Income taxes (recovery)||–||–||–||(6,023||)||(18,213||)|
|Finance expense (income), net||2,069||2,926||3,281||(136||)||(1,270||)|
|Depreciation, included in cost of sales||1,254||950||920||433||446|
|Depreciation, included in operating expenses||1,179||1,566||1,992||1,333||582|
|Amortization, included in operating expenses||249||341||1,683||1,666||1,406|
|Investment (gains) losses|
|Revaluation of financial instruments loss/(gain)||1,433||(4,955||)||(2,714||)||(297||)||(543||)|
|Share of loss from investment in joint venture||1,863||1,195||1,591||1,682||1,253|
|Loss/(gain) on convertible debentures||86||212||413||2,627||125|
|Unrealized loss on investments||4,345||311||6,553||1,671||38|
|Realized loss/(gain) on investments||–||1,217||242||(17||)||215|
|Foreign exchange loss/(gain)||1,623||(2,443||)||(617||)||46||51|
|Loss on inducement of convertible debentures||54,283||–||–||–||–|
|Non-cash fair value adjustments|
|Realized fair value amounts on inventory sold||6,656||10,764||5,447||6,663||7,285|
|Unrealized gain on changes in fair value of biological assets||(7,978||)||(6,379||)||(7,948||)||(7,051||)||(5,322||)|
|Other non-cash items|
|Share-based compensation, included in operating expenses||4,373||5,651||7,603||8,164||10,197|
|Share-based compensation, included in cost of sales||511||396||964||238||936|
|Write-off biological assets and destruction costs||–||–||–||663||–|
|Write-off of inventory||2,217||–||–||2,175||–|
|Write down of inventory to net realizable value||41,899||(1,331||)||16,089||23,041||19,335|
|Impairment loss on right-use-assets||2,000||–||476||702||–|
|Impairment loss on property, plant and equipment||46,414||220||31,606||–||–|
|Impairment of intangible assets||–||–||106,189||–||–|
|Impairment of goodwill||–||–||111,877||–||–|
|Recognition of onerous contract||1,763||–||3,000||–||–|
|Disposal of long-lived assets||122||3,237||497||–||–|
|1 Refer to the Company’s “Non-IFRS Measures” section as disclosed in the fiscal 2020 Management’s Discussion and Analysis.|
During the three months ended July 31, 2020, the Company’s Adjusted EBITDA improved 21% from the previous quarter, coming in at ($3.25M) compared with ($4.1M) for the three months ended April 30, 2020. Increased sales of Cannabis 2.0 products, while managing SG&A levels, were primary contributors to an improvement in Adjusted EBITDA. The Company’s wholesale activity and international sales also contributed, due to having higher margins, as these streams are exempt from excise taxes.
Fiscal 2020 Year Highlights
Revenue from sale of goods increased 86% for fiscal 2020, totaling $110.1M compared to $59.3M in fiscal 2019. The Company’s net revenue from sale of goods for fiscal 2020 increased 70% to $80.6M, compared with $47.3M in the prior year.
The Company strengthened its financial position by raising net cash of $186.7M during the year ended July 31, 2020 through various public and private offerings.
Operating expenses increased to $418.6M in fiscal 2020, compared to $111.5M in the prior year. Included in fiscal 2020 are several non-cash expenses, namely $111.9M impairment of goodwill, $108.2M impairment of intangible assets, $79.4M impairment of property, plant and equipment, $4.8M of restructuring costs and $4.8M loss on an onerous contract. Not including these items, operating expenses are $110.5M, down $1.6M from the prior year, even as there was a significant increase to the scale of the Company’s operations, including a number of product launches.
Loss from operations for the fiscal year was $476.6M, compared to an operating loss of $87.0M for the prior year.
The Net loss for fiscal 2020 year was $546.5M compared to $69.6M in the prior year. Included in Net loss in fiscal 2020 are the items noted above, in addition to a $54.3M loss on the inducement of convertible debentures.
The management’s discussion and analysis for the period and the accompanying financial statements and notes are available under the Company's profile on SEDAR at www.sedar.com and on its website at www.hexocorp.com.
In this press release, reference is made to gross profit before adjustment, profit/margin before fair value adjustments, adjusted gross profit/margin, adjusted EBITDA, and revenue per gram equivalent which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of a review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s Management’s Discussion and Analysis for the three months ended July 31, 2020, filed on SEDAR and EDGAR.
The Company will hold a conference call, Friday, October 30th, 2020 to discuss these results. Sebastien St-Louis, CEO, and Trent MacDonald, CFO, will host the call starting at 8:30 a.m. Eastern standard time. A question and answer period will follow management’s presentation
Date: October 30, 2020
For previous quarterly results and recent press releases, see hexocorp.com.
About HEXO Corp
HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. The Company serves the Canadian adult-use markets under its HEXO Cannabis, Up Cannabis and Original Stash brands, and the medical market under HEXO medical cannabis. For more information please visit hexocorp.com.
This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include but are not limited to the Company’s statements with respect to management’s belief that certain expenses included in operating expenses are non-recurring and related to significant changes in market conditions and the refocus of its operations on becoming Adjusted EBITDA positive.
A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.
Upcoming Life Sciences Events
- December 2020
- Pharma-Biotech Product & Company Valuation
- BioFIT 2020
- Lille: MedFIT